Could a diabetes drug curb cannabis cravings? small trial aims to find out

NCT ID NCT07265752

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tests whether tirzepatide, a drug used for diabetes, can reduce cravings in people with severe cannabis use disorder. Six adults will receive either tirzepatide or a placebo injection and then be exposed to cannabis-related cues to measure craving intensity. The goal is to see if the drug helps control cravings, which could lead to better treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Tirzepatide (a diabetes drug) given as a weekly injection
What this could lead to
If it works, this could point toward a new treatment option for cannabis use disorder by reducing cravings.
What could go wrong
This is a very small pilot study with only 6 participants, so results may not apply broadly. It is also early-phase, so safety and effectiveness are not yet established.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANNABIS USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.